格列齐特为第二代口服磺脲类降糖药,其降血糖作用是甲苯磺丁脲(第一代磺脲类降糖药)的3～30倍,主要用于治疗胰岛功能尚存的轻度、中度2型糖尿病,其降糖作用较强,临床上主要的不良反应为严重的迁延性低血糖及肝肾功能障碍,其他有呃逆、贫血、白细胞减少等不良反应。因此服用格列齐特的患者应密切监测血糖和肝肾功能。 Gliclazide is the second generation of oral sulfonylurea hypoglycemic agents, the hypoglycemic effect of tolbutamide (the first generation of sulfonylurea hypoglycemic agents) of 3 to 30 times, mainly for the treatment of surviving islet function Of mild, moderate type 2 diabetes, the hypoglycemic effect is strong, the main clinical adverse reactions are severe persistent hypoglycemia and liver and kidney dysfunction, the other with hiccups, anemia, leukopenia and other adverse reactions. Therefore, patients taking gliclazide should be closely monitored blood glucose and liver and kidney function.